T cells in myeloma.
The current trend to develop immunotherapy strategies for patients with myeloma and other B cell malignancies has stimulated considerable interest in the functional state of the T cell population in these patients. Expanded clones of T cells exist in many patients with myeloma and their presence is associated with an improved survival. However, isolating T cells with tumour specificity has proven to be a difficult task and clinical immunization trials have so far failed to achieve a significant response. There is now evidence that tumour specific T cells are either tolerized or deleted following antigen presentation and that idiotype-derived, immunodominant tumour peptides may not exist in all patients. In order to develop more effective immunotherapy strategies for patients with myeloma, further studies are urgently required to identify the most appropriate tumour antigen, the nature of the interactions which take place during antigen presentation, and how to promote the cytotoxicity of autologous T cells.
Raitakari
M
M
Department of Clinical Chemistry, Turku University Central Hospital, Turku, Finland.
Brown
R D
RD
Gibson
J
J
Joshua
D E
DE
D015496:CD4-Positive T-Lymphocytes / Q000166:cytology; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology; D006801:Humans; D007130:Immunoglobulin Idiotypes; D016130:Immunophenotyping; D009101:Multiple Myeloma / Q000378:metabolism*; D010455:Peptides / Q000737:chemistry; D013601:T-Lymphocytes / Q000166:cytology* / Q000378:metabolism; D013997:Time Factors
D007130:Immunoglobulin Idiotypes; D010455:Peptides